2,252
Views
19
CrossRef citations to date
0
Altmetric
Research Articles

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo

, , , , , , , , , , & show all
Pages 3291-3303 | Received 09 Sep 2022, Accepted 25 Oct 2022, Published online: 09 Nov 2022

References

  • Alvarez-Erviti L, Seow Y, Yin H, et al. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–5. Epub 2011 Mar 20. PMID: 21423189.
  • Anninga JK, Gelderblom H, Fiocco M, et al. (2011). Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47:2431–45. Epub 2011 Jun 22. PMID: 21703851.
  • Barenholz Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–34. Epub 2012 Mar 29. PMID: 22484195.
  • Chen C, Sun M, Wang J, et al. (2021). Active cargo loading into extracellular vesicles: highlights the heterogeneous encapsulation behaviour. J Extracell Vesicles 10:e12163. PMID: 34719860; PMCID: PMC8558234.
  • Colao IL, Corteling R, Bracewell D, Wall I. (2018). Manufacturing exosomes: a promising therapeutic platform. Trends Mol Med 24:242–56. Epub 2018 Feb 12. PMID: 29449149.
  • Freyer DR, Seibel NL. (2015). The clinical trials gap for adolescents and young adults with cancer: recent progress and conceptual framework for continued research. Curr Pediatr Rep 3:137–45. Epub 2015 Feb 18. PMID: 30613438; PMCID: PMC6319956.
  • Goh WJ, Lee CK, Zou S, et al. (2017). Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. Int J Nanomed 12:2759–67. PMID: 28435256; PMCID: PMC5388236.
  • Goh WJ, Zou S, Ong WY, et al. (2017). Bioinspired cell-derived nanovesicles versus exosomes as drug delivery systems: a cost-effective alternative. Sci Rep 7:14322. PMID: 29085024; PMCID: PMC5662560.
  • Gomari H, Forouzandeh Moghadam M, Soleimani M, et al. (2019). Targeted delivery of doxorubicin to HER2 positive tumor models. Int J Nanomed 14:5679–5690. Erratum in: Int J Nanomed (2019). 14:7919. PMID: 31413568; PMCID: PMC6662522.
  • Guo P, Busatto S, Huang J, et al. (2021). A facile magnetic extrusion method for preparing endosome-derived vesicles for cancer drug delivery. Adv Funct Mater 31:2008326. Epub 2021 Jan 20. PMID: 34924915; PMCID: PMC8680268.
  • Hu L, Wickline SA, Hood JL. (2015). Magnetic resonance imaging of melanoma exosomes in lymph nodes. Magn Reson Med 74:266–71. Epub 2014 Jul 22. PMID: 25052384; PMCID: PMC4422779.
  • Jaffe N. (2009). Osteosarcoma: review of the past, impact on the future. The American experience. In: Jaffe N, Bruland OS, Bielack S, eds. Pediatric and adolescent osteosarcoma. Boston: Springer, 239.
  • Jang SC, Kim OY, Yoon CM, et al. (2013). Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7:7698–710. Epub 2013 Sep 4. Erratum in: ACS Nano (2014). 8:1073. PMID: 24004438.
  • Jiang L, Vader P, Schiffelers RM. (2017). Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy. Gene Ther 24:157–66. Epub 2017 Jan 31. PMID: 28140387.
  • Kamerkar S, LeBleu VS, Sugimoto H, et al. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546:498–503. Epub 2017 Jun 7. PMID: 28607485; PMCID: PMC5538883.
  • Kim MS, Haney MJ, Zhao Y, et al. (2016). Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12:655–64. Epub 2015 Nov 14. PMID: 26586551; PMCID: PMC4809755.
  • Li S, Wang X. (2021). The potential roles of exosomal noncoding RNAs in osteosarcoma. J Cell Physiol 236:3354–65. Epub 2020 Oct 12. PMID: 33044018.
  • Li S, Zhang T, Xu W, et al. (2018). Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics 8:1361–1375. Erratum in: Theranostics (2020). 10:5530–1. PMID: 29507626; PMCID: PMC5835942.
  • Li X, Wang L, Wang L, et al. (2020). Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles. Biomater Sci 8:5888–99. PMID: 33001086.
  • Li Z, Huang J, Du T, et al. (2022). Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766. Chin Chem Lett 33:2496–500.
  • Liu Y, Qiao Z, Gao J, et al. (2021). Hydroxyapatite-bovine serum albumin-paclitaxel nanoparticles for locoregional treatment of osteosarcoma. Adv Healthc Mater 10:e2000573. Epub 2020 Nov 9. PMID: 33166086.
  • Liu Y, Xia Y, Smollar J, et al. (2021). The roles of small extracellular vesicles in lung cancer: Molecular pathology, mechanisms, diagnostics, and therapeutics. Biochim Biophys Acta Rev Cancer 1876:188539. Epub 2021 Apr 20. PMID: 33892051.
  • Meyers PA. (2015). Systemic therapy for osteosarcoma and Ewing sarcoma. Am Soc Clin Oncol Educ Book e644-7. PMID: 25993235.
  • Reiner AT, Witwer KW, van Balkom BWM, et al. (2017). Concise review: developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl Med 6:1730–9. Epub 2017 Jul 17. PMID: 28714557; PMCID: PMC5689784.
  • Shu S, Yang Y, Allen CL, et al. (2020). Purity and yield of melanoma exosomes are dependent on isolation method. J Extracell Vesicles 9:1692401. PMID: 31807236; PMCID: PMC6882439.
  • Song H, Zhao J, Cheng J, et al. (2021). Extracellular vesicles in chondrogenesis and cartilage regeneration. J Cell Mol Med 25:4883–92. Epub 2021 May 4. PMID: 33942981; PMCID: PMC8178250.
  • Srivastava A, Amreddy N, Babu A, et al. (2016). Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep 6:38541. PMID: 27941871; PMCID: PMC5150529.
  • Tang T, Martin P, Somasundaram N, et al. (2021). Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma. Haematologica 106:3170–5. PMID: 33147935; PMCID: PMC8634181.
  • van Niel G, D’Angelo G, Raposo G. (2018). Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19:213–28. Epub 2018 Jan 17. PMID: 29339798.
  • Wei H, Chen J, Wang S, et al. (2019). A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro. Int J Nanomed 14:8603–10. PMID: 31802872; PMCID: PMC6830377.
  • Wenningmann N, Knapp M, Ande A, et al. (2019). Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol 96:219–32. Epub 2019 Jun 4. PMID: 31164387.
  • Wu JY, Li YJ, Hu XB, et al. (2021). Exosomes and biomimetic nanovesicles-mediated anti-glioblastoma therapy: a head-to-head comparison. J Control Release 336:510–21. Epub 2021 Jul 6. PMID: 34237399.
  • Wu K, Yu B, Li D, et al. (2022). Recent advances in nanoplatforms for the treatment of osteosarcoma. Front Oncol 12:805978. PMID: 35242707; PMCID: PMC8885548.
  • Zhang XB, Zhang RH, Su X, et al. (2021). Exosomes in osteosarcoma research and preclinical practice. Am J Transl Res 13:882–97. PMID: 33841628; PMCID: PMC8014357.
  • Zheng Y, You X, Chen L, et al. (2019). Biotherapeutic nanoparticles of poly(ferulic acid) delivering doxorubicin for cancer therapy. J Biomed Nanotechnol 15:1734–43. PMID: 31219014.
  • Zhu Q, Ling X, Yang Y, et al. (2019). Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Adv Sci (Weinh) 6:1801899. PMID: 30937268; PMCID: PMC6425428.
  • Zhuang X, Xiang X, Grizzle W, et al. (2011). Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 19:1769–79. Epub 2011 Sep 13. Erratum in: Mol Ther (2012). 20:239. PMID: 21915101; PMCID: PMC3188748.